[Caliway] CBL-514 Phase 2 Clinical Trial for Fat Reduction Approved in Australia
NQ Score
0/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Caliway Biopharmaceuticals announced that its new drug CBL-514 injection for subcutaneous fat reduction received HREC approval in Australia for a Phase 2 trial.